Anavex Life Sciences Corp (AVXL)

[JB3729]

AVXL may assume a lot of unnecessary risk by extending the PART B again. The first extension made sense in that donepezil becomes pretty much worthless at 12 months. The 12 month comparison should look really good for A2-73.

Should A2-73's results become less remarkable after 12 months, it could hurt AVXL's partnering position and it's ability to gain grants.

If AVXL already had Phase 3 funding, the extension would make more sense.

However, the Company may not see additional risk.

IMHO